APA (7th ed.) Citation

C, H., CM, C., MP, M., L, W., G, A., A, W., . . . C, S. (2021). Rituximab-Lenalidomide-Ibrutinib Combination for Relapsed/Refractory Primary CNS Lymphoma: A Case Series of the LOC Network. Neurology, 97(13), 628. https://doi.org/10.1212/WNL.0000000000012515

Chicago Style (17th ed.) Citation

C, Houillier, Chabrot CM, Moles-Moreau MP, Willems L, Ahle G, Waultier-Rascalou A, Fornecker LM, Hoang-Xuan K, and Soussain C. "Rituximab-Lenalidomide-Ibrutinib Combination for Relapsed/Refractory Primary CNS Lymphoma: A Case Series of the LOC Network." Neurology 97, no. 13 (2021): 628. https://doi.org/10.1212/WNL.0000000000012515.

MLA (9th ed.) Citation

C, Houillier, et al. "Rituximab-Lenalidomide-Ibrutinib Combination for Relapsed/Refractory Primary CNS Lymphoma: A Case Series of the LOC Network." Neurology, vol. 97, no. 13, 2021, p. 628, https://doi.org/10.1212/WNL.0000000000012515.